Therefore, we aimed to epigenetically increase FAS levels on neuroblastoma cells to unleash this antigen-independent killing pathway and improve CAR T cell efficacy against neuroblastomas with heterogeneous or low target antigen expression. Here, FAS is linked to neuroblastoma.